Stock listing
Dusseldorf:BX20 BioXcel Therapeutics, Inc. Aktie
German listing (Dusseldorf) of BioXcel Therapeutics, Inc. · home listing NASDAQ:BTAI
Follow BioXcel Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BTAI
$0.013 USD -0.000 (-3.6%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BTAI · Data provided by Twelve Data
- Day range
- $0.012 – $0.016 USDOct 30, 2026
- Volume
- 114,934 sharesOct 30, 2026
- Market cap
- $406,965 USDAt the close on Oct 30, 2026 · price × 31.30M shares outstanding
- 52-week range
- $0.012 – $2.329 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $1.10M USDMedian day 695,500 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BTAI · Home | $0.013 USD | 0.000 (-3.6%) | 114,934 | $0.012 | $0.016 | $0.012 | $0.013 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:BTAI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.013 | 0.000 | -3.6% | $0.012 | $0.016 | $0.012 | 114,934 | |
| $0.013 | -0.002 | -13.0% | $0.016 | $0.017 | $0.012 | 119,152 | |
| $0.016 | +0.002 | +14.6% | $0.012 | $0.016 | $0.012 | 132,057 | |
| $0.014 | -0.002 | -14.9% | $0.016 | $0.016 | $0.012 | 45,828 | |
| $0.016 | -0.032 | -66.8% | $0.013 | $0.016 | $0.012 | 151,009 | |
| $0.048 | -0.002 | -3.3% | $0.045 | $0.055 | $0.040 | 70,578 | |
| $0.050 | -0.003 | -6.2% | $0.056 | $0.056 | $0.044 | 169,927 | |
| $0.053 | +0.006 | +13.3% | $0.047 | $0.070 | $0.047 | 278,004 | |
| $0.047 | -0.005 | -10.5% | $0.047 | $0.062 | $0.040 | 202,641 | |
| $0.052 | +0.007 | +15.6% | $0.050 | $0.060 | $0.045 | 347,160 | |
| $0.045 | -0.004 | -9.0% | $0.046 | $0.050 | $0.041 | 220,560 | |
| $0.049 | +0.000 | +1.0% | $0.049 | $0.060 | $0.043 | 422,760 | |
| $0.049 | +0.008 | +19.2% | $0.031 | $0.052 | $0.031 | 1,047,987 | |
| $0.041 | +0.003 | +7.0% | $0.041 | $0.041 | $0.035 | 623,491 | |
| $0.038 | +0.003 | +8.8% | $0.035 | $0.050 | $0.034 | 289,346 | |
| $0.035 | -0.010 | -21.6% | $0.047 | $0.051 | $0.032 | 391,678 | |
| $0.045 | +0.000 | +1.0% | $0.052 | $0.052 | $0.032 | 838,101 | |
| $0.045 | -0.017 | -27.6% | $0.052 | $0.069 | $0.040 | 1,115,914 | |
| $0.062 | +0.004 | +6.0% | $0.051 | $0.070 | $0.051 | 291,674 | |
| $0.058 | -0.017 | -22.8% | $0.061 | $0.075 | $0.051 | 153,616 | |
| $0.075 | +0.008 | +12.3% | $0.063 | $0.080 | $0.050 | 308,741 | |
| $0.067 | +0.022 | +49.7% | $0.049 | $0.071 | $0.041 | 1,165,050 | |
| $0.045 | 0.000 | -0.9% | $0.040 | $0.050 | $0.040 | 597,837 | |
| $0.045 | -0.006 | -11.6% | $0.040 | $0.055 | $0.032 | 509,413 | |
| $0.051 | +0.001 | +2.0% | $0.052 | $0.058 | $0.045 | 485,472 | |
| $0.050 | +0.003 | +6.4% | $0.044 | $0.057 | $0.040 | 953,200 | |
| $0.047 | +0.004 | +9.5% | $0.043 | $0.060 | $0.034 | 4,103,000 | |
| $0.043 | -0.031 | -41.9% | $0.019 | $0.044 | $0.019 | 6,288,291 | |
| $0.074 | -0.044 | -37.4% | $0.091 | $0.094 | $0.069 | 47,480,718 | |
| $0.118 | +0.011 | +10.3% | $0.120 | $0.127 | $0.110 | 151,001,600 | |
| $0.107 | -0.030 | -21.9% | $0.130 | $0.197 | $0.106 | 46,794,600 | |
| $0.137 | -0.026 | -16.0% | $0.140 | $0.142 | $0.120 | 15,689,100 | |
| $0.163 | -0.018 | -9.9% | $0.151 | $0.170 | $0.142 | 10,782,700 | |
| $0.181 | -0.538 | -74.8% | $0.224 | $0.230 | $0.157 | 58,562,800 | |
| $0.719 | -0.061 | -7.8% | $0.749 | $0.763 | $0.700 | 1,084,200 | |
| $0.780 | +0.038 | +5.1% | $0.758 | $0.785 | $0.736 | 900,300 | |
| $0.742 | -0.019 | -2.5% | $0.783 | $0.811 | $0.711 | 1,580,400 | |
| $0.761 | -0.043 | -5.3% | $0.800 | $0.833 | $0.751 | 1,119,800 | |
| $0.804 | +0.005 | +0.6% | $0.810 | $0.859 | $0.792 | 1,239,600 | |
| $0.799 | -0.028 | -3.4% | $0.840 | $0.840 | $0.798 | 902,300 | |
| $0.827 | +0.035 | +4.4% | $0.790 | $0.864 | $0.790 | 797,600 | |
| $0.792 | -0.098 | -11.0% | $0.850 | $0.896 | $0.780 | 1,848,100 | |
| $0.890 | -0.300 | -25.2% | $1.030 | $1.030 | $0.850 | 2,199,600 | |
| $1.190 | +0.060 | +5.3% | $1.110 | $1.240 | $1.015 | 2,031,400 | |
| $1.130 | +0.070 | +6.6% | $1.100 | $1.160 | $1.050 | 1,087,200 | |
| $1.060 | +0.128 | +13.7% | $0.960 | $1.090 | $0.960 | 1,112,500 | |
| $0.932 | +0.004 | +0.4% | $0.965 | $1.020 | $0.922 | 922,500 | |
| $0.928 | +0.026 | +2.9% | $0.900 | $0.958 | $0.893 | 639,100 | |
| $0.902 | +0.072 | +8.7% | $0.840 | $0.920 | $0.840 | 526,200 | |
| $0.830 | -0.011 | -1.3% | $0.840 | $0.850 | $0.800 | 355,400 | |
| $0.841 | -0.020 | -2.3% | $0.870 | $0.886 | $0.840 | 319,900 | |
| $0.861 | +0.013 | +1.5% | $0.860 | $0.890 | $0.860 | 457,400 | |
| $0.848 | +0.040 | +5.0% | $0.814 | $0.880 | $0.800 | 695,500 | |
| $0.808 | +0.015 | +1.9% | $0.794 | $0.840 | $0.780 | 499,500 | |
| $0.793 | -0.009 | -1.1% | $0.790 | $0.813 | $0.746 | 763,400 |
- Ticker
- Dusseldorf:BX20
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
May 28, 2026
Closed $1.26 (-3.8%) on May 28, 2026
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026
Closed $1.14 (-5.8%) on May 15, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Apr 17, 2026
Closed $1.15 (+7.5%) on Apr 17, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Apr 8, 2026
Closed $1.10 (+0.9%) on Apr 8, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Apr 1, 2026
Closed $1.22 (-9.0%) on Apr 1, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting
Mar 30, 2026
Closed $1.21 (-4.0%) on Mar 30, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Mar 11, 2026
Closed $1.57 (+1.3%) on Mar 11, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
Mar 10, 2026
Closed $1.55 (-10.4%) on Mar 10, 2026
BioXcel Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 173 in all · newest May 28, 2026 · oldest 2019
- Calls
- 14 calls with a replay · 14 with a transcript · latest Nov 14, 2024
- Decks
- 22 decks · latest November 2025
Where BioXcel Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BTAI · Home listing | NASDAQ | United States | USD |
| BOATS:BTAI | BOATS | United States | USD |
| LS Exchange:A40YSR | LS Exchange | Germany | EUR |
| gettex:BX20 | gettex | Germany | EUR |
| Lang & Schwarz:A40YSR | Lang & Schwarz | Germany | EUR |
| Tradegate:BX20 | Tradegate | Germany | EUR |
| Dusseldorf:BX20 · This page | Dusseldorf | Germany | EUR |
| Frankfurt:BX20 | Frankfurt | Germany | EUR |
| Hamburg:BX20 | Hamburg | Germany | EUR |
| Munich:BX20 | Munich | Germany | EUR |
| Stuttgart:BX20 | Stuttgart | Germany | EUR |
Valuation
EV/sales 124× against a median of −0.1×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Oct 30, 2026
- Enterprise value
- $92.02M USD
- P/E
- Loss
- EV/sales
- 124×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 53.1%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.39
Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics, Inc. · NASDAQ:BTAI | US$406,965 | US$92.02M | n/a | 124× | n/a | n/a | n/a | n/a | 2.39 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,522 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| Median of the others | US$398,231 | −US$97,481 | 0.7× | −0.1× | 0.2× | −222.3% | 0.0× | 1.14 |
Team and board
| Officer | Role |
|---|---|
| Vimal Mehta | Chief Executive Officer & Founder |
| Richard I. Steinhart | Senior Vice President and Chief Financial Officer |
| Javier Rodriguez | Senior Vice President, Chief Legal Officer, and Corporate Secretary |
| Frank D. Yocca | Chief Scientific Officer |
Events
| Call | When | Status |
|---|---|---|
| BioXcel Therapeutics (NASDAQ:BTAI) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q4 2023 Earnings Call | Tue, Mar 12, 2024 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q1 2023 Earnings Call | Mon, May 08, 2023 · 8:00 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q4 2022 Earnings Call | Thu, Mar 09, 2023 · 8:30 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:30 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 8:30 AM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| BioXcel Therapeutics (NASDAQ:BTAI) Q1 2022 Earnings Call | Mon, May 09, 2022 · 8:30 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q4 2021 Earnings Call | Thu, Mar 10, 2022 · 8:30 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 8:30 AM ET | Replay |
| BioXcel Therapeutics (NASDAQ:BTAI) Q2 2021 Earnings Call | Tue, Aug 10, 2021 · 8:30 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 45 slides | November 2025 |
| Technical Presentation (August 2025) | Technical | 24 slides | Aug 27, 2025 |
| Investor Presentation (August 2025) | Investor deck | 15 slides | Aug 11, 2025 |
| Investor Presentation (April 2024) | Investor deck | 36 slides | Apr 22, 2024 |
| Corporate Update (April 2024) | Corporate update | 8 slides | Apr 10, 2024 |
| Investor Presentation (February 2024) | Investor deck | 42 slides | Feb 14, 2024 |
| Investor Day (December 2023) | Investor day | 59 slides | Dec 12, 2023 |
| Investor Presentation (October 2023) | Investor deck | 27 slides | Oct 10, 2023 |
| Technical Presentation (February 2023) | Technical | 86 slides | Feb 21, 2023 |
| Technical Presentation (February 2023) | Technical | 5 slides | Feb 21, 2023 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 41st Annual J.P. Morgan Healthcare Conference 2023 | Conference | 28 slides | Jan 11, 2023 |
| Investor Day (October 2022) | Investor day | 96 slides | Oct 18, 2022 |
| Investor Presentation (September 2022) | Investor deck | 7 slides | Sep 12, 2022 |
| Corporate Update (2022) | Corporate update | 10 slides | 2022 |
| Investor Presentation (April 2020) | Investor deck | 30 slides | Apr 15, 2020 |
| Investor Presentation (December 2019) | Investor deck | 26 slides | December 2019 |
| Corporate Update (July 2019) | Corporate update | 21 slides | Jul 22, 2019 |
| Investor Presentation (May 2019) | Investor deck | 17 slides | May 20, 2019 |
| Investor Presentation (March 2019) | Investor deck | 35 slides | Mar 12, 2019 |
| Corporate Update (January 2019) | Corporate update | 16 slides | Jan 3, 2019 |
| Investor Presentation (June 2018) | Investor deck | 26 slides | Jun 7, 2018 |
| Investor Presentation (May 2018) | Investor deck | 27 slides | May 21, 2018 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Closed: US$11.5M raised | Aug 12, 2025 |
| Warrant exercise of outstanding warrants Closed: US$3.6M raised | Aug 12, 2025 |
| Registered direct offering of shares of common stock (or common stock equivalents) and accompanying warrants Closed: US$14M raised · US$3.5 a share · Warrants at US$4.2 for 60 months · Rodman & Renshaw LLC Dealers: Rodman & Renshaw LLC (lead) Use of proceeds: Working capital and general corporate purposes | Mar 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$11.00 a share on Mar 7, 2018.
- Price
- US$11.00 a share
- Shares offered
- 5,454,545 shares of common stock
- Offering size
- US$60 million
- Underwriters' option
- Up to 818,181 more shares
- Listing
- BTAI on the Nasdaq Capital Market
- Underwriters
- Barclays, UBS Investment Bank, BMO Capital Markets, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Mar 12, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 13, 2017 |
| Filed publicly | Feb 12, 2018 |
| Amended 3 times | Newest Mar 5, 2018 |
| Shares registered with an exchange | Mar 5, 2018 |
| Declared effective by the SEC | Mar 7, 2018 |
| Final prospectus, with the price | Mar 9, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 9, 2018 |
| EFFECT · Notice that a registration is effective | Mar 7, 2018 |
| CORRESP · Letter to the SEC | Mar 5, 2018 |
| CORRESP · Letter to the SEC | Mar 5, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 5, 2018 |
| FWP · Free writing prospectus | Mar 5, 2018 |
| S-1/A · Registration statement, amended | Mar 5, 2018 |
| S-1/A · Registration statement, amended | Feb 27, 2018 |
| S-1/A · Registration statement, amended | Feb 26, 2018 |
| CORRESP · Letter to the SEC | Feb 23, 2018 |
All 23 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Feb 23, 2018 |
| S-1 · Registration statement | Feb 12, 2018 |
| CORRESP · Letter to the SEC | Feb 12, 2018 |
| CORRESP · Letter to the SEC | Feb 12, 2018 |
| UPLOAD · Letter from the SEC | Feb 5, 2018 |
| DRSLTR · Letter to the SEC with a draft | Jan 26, 2018 |
| DRS/A · Draft registration statement, amended | Jan 26, 2018 |
| UPLOAD · Letter from the SEC | Jan 16, 2018 |
| DRSLTR · Letter to the SEC with a draft | Dec 27, 2017 |
| DRS/A · Draft registration statement, amended | Dec 26, 2017 |
| DRSLTR · Letter to the SEC with a draft | Dec 22, 2017 |
| UPLOAD · Letter from the SEC | Dec 12, 2017 |
| DRS · Draft registration statement | Nov 13, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 9, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 642.0K | 2.27M | 1.38M | 375.0K | |||||
| Cost of revenue | 164.0K | 2.14M | 1.26M | 20.0K | |||||
| Gross profit | 478.0K | 123.0K | 120.0K | 355.0K | |||||
| Research and development | 30.3M | 30.4M | 84.3M | 91.2M | 52.7M | 58.0M | 25.8M | 14.6M | 2.69M |
| Selling, general and administrative | 20.5M | 34.5M | 83.4M | 68.8M | 54.2M | ||||
| Operating income | -50.5M | -67.2M | -171.8M | -159.6M | -106.9M | -82.3M | -33.6M | -20.0M | -4.54M |
| Depreciation and amortization | 300.0K | 309.0K | 318.0K | 327.0K | 297.0K | 188.0K | 156.0K | 17.0K | 1.00K |
| EBITDA | -50.2M | -66.9M | -171.5M | -159.3M | -106.6M | -82.1M | -33.4M | -19.9M | -4.54M |
| Interest expense | 17.0M | 15.1M | 13.3M | 8.21M | 40.0K | 27.0K | 20.0K | ||
| Income tax | 0 | 0 | 0 | ||||||
| Net income | -69.9M | -59.6M | -179.1M | -165.8M | -106.9M | -82.2M | -33.0M | -19.3M | -4.54M |
| Earnings per share, basic | -5.73 | -23.51 | -98.33 | -5.92 | -4.05 | -3.79 | -2.02 | -1.32 | -0.47 |
| Earnings per share, diluted | -5.73 | -23.51 | -98.33 | -5.92 | -4.05 | -3.79 | -2.02 | -1.32 | -0.47 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 28.4M | 29.9M | 65.2M | 193.7M | 233.0M | 213.1M | 32.4M | 42.6M | 887.0K |
| Receivables | 233.0K | 131.0K | 71.0K | 248.0K | |||||
| Inventory | 722.0K | 679.0K | 1.99M | 1.99M | |||||
| Current assets | 44.7M | 37.4M | 72.1M | 202.9M | 236.8M | 217.1M | 34.1M | 43.2M | 890.0K |
| Property, plant and equipment | 175.0K | 475.0K | 784.0K | 1.08M | 1.29M | 1.27M | 1.04M | 327.0K | 4.00K |
| Total assets | 44.9M | 38.3M | 73.7M | 205.9M | 239.4M | 219.9M | 36.4M | 43.5M | 1.35M |
| Accounts payable | 14.7M | 16.0M | 13.7M | 10.2M | 4.68M | 3.98M | 4.95M | 1.60M | 444.0K |
| Current liabilities | 53.9M | 22.2M | 27.3M | 32.9M | 16.7M | 11.8M | 8.47M | 4.66M | 2.34M |
| Long-term debt | 84.7M | 102.5M | 100.6M | 93.1M | |||||
| Total debt | 109.6M | 102.5M | 100.6M | 93.1M | |||||
| Total liabilities | 140.4M | 131.4M | 130.2M | 129.1M | 17.8M | 13.2M | 9.50M | 4.66M | 2.34M |
| Shareholders' equity | -95.5M | -93.1M | -56.5M | 76.8M | 221.7M | 206.7M | 26.9M | 38.9M | -982.0K |
| Shares outstanding | 22.3M | 3.10M | 1.87M | 28.1M | 28.0M | 24.4M | 18.1M | 15.7M | 9.91M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -57.6M | -72.0M | -155.0M | -135.3M | -82.2M | -66.3M | -27.1M | -13.5M | -2.20M |
| Capital spending | 0 | 0 | -20.0K | -139.0K | -445.0K | -316.0K | -870.0K | -340.0K | |
| Free cash flow | -57.6M | -72.0M | -155.0M | -135.5M | -82.6M | -66.7M | -28.0M | -13.8M | |
| Cash from investing | 0 | 0 | -20.0K | -139.0K | -445.0K | -316.0K | -870.0K | -340.0K | |
| Cash from financing | 56.5M | 36.7M | 26.5M | 96.2M | 102.4M | 247.4M | 17.8M | 55.5M | 3.08M |
| Share buybacks | -9.02M | ||||||||
| Change in cash | -1.10M | -35.4M | -128.5M | -39.2M | 19.8M | 180.7M | -10.1M | 41.7M | 887.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| NT 10-Q · Late filing notice | Nov 17, 2026 | Explanation request | SEC |
| 8-K · Current report | Oct 30, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 1, 2026 | Financing | SEC |
| 8-K · Current report | Aug 28, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 25, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 24, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 11, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 3, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2026 | Financing | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 30, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 11, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Nov 12, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 12, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Oct 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 424B5 · Prospectus | Aug 18, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 8-K · Current report | Aug 15, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Aug 11, 2025 | Current report | SEC |
| 8-K · Current report | Aug 11, 2025 | Current report | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 424B5 · Prospectus | Aug 6, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 21, 2025 | Current report | SEC |
| 8-K · Current report | Jul 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 4, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 8-K · Current report | Mar 21, 2025 | Current report | SEC |
| 8-K · Current report | Mar 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 4, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jan 15, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Jan 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Dec 30, 2024 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 18, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 18, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 18, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Material contract | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 25, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Nov 25, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Nov 21, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Oct 9, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 20, 2024 | Current report | SEC |
| 8-K · Current report | Sep 19, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
This page holds 200 of 673 filings. Open Filings
Cap table
Built by 6ix from BioXcel Therapeutics, Inc.’s releases · as of Aug 12, 2025
- Common shares
- 31,305,000
- Fully diluted
- 31,305,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 31,305,000 |
Warrants and options
| Lot |
|---|
| Warrants · US$4.20 · expire about Mar 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 31,305,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajiv Patni Other companies: Septerna, Inc. (Chief Medical Officer · Since at least Aug 24, 2026); Quince Therapeutics, Inc. (Director · Since at least Feb 15, 2024); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past) | Director · Since at least Jan 15, 2025 |
| Michael P. Miller Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Feb 1, 2026); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); Jazz Pharmaceuticals plc (EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past) | Director · Since at least Jul 1, 2022 |
| Richard I. Steinhart Other companies: Atossa Therapeutics, Inc. (Director · Since at least Mar 1, 2014); Actinium Pharmaceuticals, Inc. (Delaware) (Director · Since at least Nov 8, 2013); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past) | Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018 |
| Matthew T Wiley Other companies: Definium Therapeutics, Inc. (Chief Commercial Officer · Since at least Mar 17, 2025); VYNE Therapeutics Inc. (Chief Commercial Officer · Sep 30, 2020 – Jun 30, 2021 · Past) | Chief Commercial Officer · Jan 17, 2022 – Sep 17, 2024 · Past |
| Sandeep Steve Laumas Other companies: Unicycive Therapeutics, Inc. (Director · Since at least Jul 12, 2021); Instil Bio, Inc. (Chief Financial Officer & Chief Business Officer · Since at least Mar 18, 2021) | Director · Since at least Mar 7, 2018 |
| William P Kane Jr Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); Karuna Therapeutics Inc (Chief Commercial Officer · Feb 6, 2023 – Mar 18, 2024 · Past) | Chief Commercial Officer · Jun 15, 2020 – Aug 16, 2021 · Past |
| David J Mack Other companies: Ambipar Emergency Response (Director · Since at least Mar 18, 2026) | Director · Since at least Nov 21, 2024 |
| June Bray Other companies: Quince Therapeutics, Inc. (Director · Since at least Jun 9, 2022) | Director · Since at least Mar 1, 2021 |
| Michal Votruba Other companies: Emmaus Life Sciences, Inc. (Director · Jul 30, 2015 – Oct 8, 2018 · Past) | Director · Since at least Mar 7, 2019 |
| Susan E Atkins Other companies: Jefferson Capital, Inc. (Director · Since at least Mar 18, 2026) | Director · Since at least Aug 12, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Vincent O'Neill Other companies: Synlogic Inc (Chief Medical Officer · Apr 25, 2016 – Apr 25, 2016 · Past) | See Remarks · Mar 7, 2018 – Dec 14, 2024 · Past |
| Frank D. Yocca | Chief Scientific Officer · Since at least Mar 7, 2018 |
| Javier Rodriguez | Senior Vice President, Chief Legal Officer, and Corporate Secretary · Since at least Feb 22, 2021 |
| Krishnan Nandabalan | Director · Jul 24, 2020 – Apr 6, 2023 · Past |
| Peter Mueller | Director · Since at least Jun 11, 2021 |
| Reina Benabou | See Remarks · Jun 22, 2020 – Jun 22, 2020 · Past |
| Vimal Mehta | CEO and President, Director · Since at least May 23, 2019 |
Log in to ask 6ix AI your own questions about BioXcel Therapeutics, Inc.